On the fly News and insights, exclusive to thefly.com

MRNA

Moderna

$57.53 /

-4.1 (-6.65%)

13:13
07/02/20
07/02
13:13
07/02/20
13:13

Moderna falls after STAT says large COVID-19 vaccine study delayed

A 30,000-patient trial of Moderna's coronavirus vaccine candidate which was expected to start next week has been delayed, Damian Garde of STAT reports. Moderna is making changes to the trial plan, which has pushed back the expected start date of the Phase 3 study, Garde says, citing investigators. The investigators, who spoke on condition of anonymity, emphasized that protocol changes are common but said it's not clear how long the start will be delayed, he added. Shares of Moderna are down 5% to $58.64 following the report. Following the STAT report, Moderna CEO Stephane Bancel told CNBC following that the trial is on track to start in July. Reference Link

  • 12

    Feb

  • 19

    May

MRNA Moderna
$57.53 /

-4.1 (-6.65%)

07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/26/20 Morgan Stanley
Morgan Stanley says Axios overstates contention on Moderna-NIH vaccine ownership

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.